CClinicalTrials.gg
CompletedNCT06536270Updated Jan 22, 2025

Development of a Web-Based Food Frequency Questionnaire and Diet Quality Score for Turkish Adults

An observational study in Nutritional Assessments and Nutritional Quality, sponsored by Medipol University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Medipol University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
151
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This research aims to adapt and validate the web-based eNutri Food Frequency Questionnaire (FFQ) and Diet Quality Score (DQS) for the Turkish population, addressing the current gap in dietary assessment tools for Turkey. The study involves adapting the UK-based eNutri FFQ to reflect Turkish dietary habits, including revising the food list, capturing portion size photos, and incorporating local food composition data. The revised FFQ will be validated against three 24-hour dietary recalls and tested for reproducibility.

Read the detailed description

Background: Non-communicable diseases (NCDs), such as cardiovascular diseases, are important global health concerns. Accurate dietary assessment is pivotal in understanding the relationship between food intake and health outcomes. Presently, there is a notable absence of a comprehensive dietary assessment tool tailored for the Turkish population.

Objective: The primary objective of this research is to adapt and validate the web-based eNutri Food Frequency Questionnaire (FFQ) and Diet Quality Score (DQS) for the Turkish population, addressing the current gap in dietary assessment methods.

Design and Proposed Analysis: The first part of the study will involve adapting the UK-based e-Nutri FFQ to reflect dietary habits of Turkish adults (eNutri-Turkey), such as revising the food list, taking portion size photos, and incorporating Turkish food composition data. The revised FFQ delivered online will be validated against three 24-hour recalls by phone (reference method) and the FFQ will be administered twice to assess reproducibility. The study will employ Cronbach's Alpha for internal consistency and the Bland-Altman method for validity. Additionally, inter-rater reliability and reproducibility will be assessed through Cohen's Kappa and ICC analysis, respectively. The eNutri DQS will be adapted in accordance with Turkish dietary guidelines. Following the adaptation, its validity will be assessed using existing Turkish population nutrient data. This analysis will involve retrospectively calculating the DQS and examining its associations with key risk markers of chronic diseases (BMI, blood pressure, blood glucose and cholesterol levels). Additionally, two qualitative studies will be conducted before starting the validation study. Dietitians and nutrition academics from Turkey (n=10) will provide insights on the suitability and effectiveness of eNutri-Turkey through one-to-one interviews. Feedback received will be used to improve the FFQ and DQS.

02

Conditions studied

  • Nutritional Assessments
  • Nutritional Quality

Keywords

  • Food Frequency Questionnaire
  • Dietary Assessment
  • Diet Quality
03

In context

Lead sponsor

Medipol University is the lead sponsor of 311 studies on the registry; 86 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of Turkish adults aged 18-65 years who reside in Turkey.

Inclusion criteria

  • Adults aged 18-65 years.
  • No diagnosed medical conditions (e.g., diabetes, heart disease, cancer, gastrointestinal conditions).
  • Not pregnant or lactating.
  • No food allergies or intolerances.
  • Not following a specialized diet (e.g., vegan, weight-loss, sports nutrition regimen; vegetarians are eligible).
  • Not receiving face-to-face nutritional services or dietary advice from a medical professional.
  • Not participating in another nutrition study.
  • Residing in Turkey.

Exclusion criteria

Exclusion Criteria:

  • Individuals with any diagnosed medical conditions.
  • Pregnant or lactating women.
  • Individuals with food allergies or intolerances.
  • Those following a specialized diet (except vegetarians).
  • Participants currently receiving face-to-face nutritional services or dietary advice.
  • Individuals involved in another nutrition study.
  • Individuals residing outside of Turkey.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
151 participants (actual)
Target follow-up
2 Weeks
Patient registry
Yes

Interventions

  • OtherA validation and reproducibility study with a cross-sectional component

    The primary intervention in this study involves adapting and validating the eNutri web-based Food Frequency Questionnaire and Diet Quality Score for the Turkish population.

06

What researchers measure

Primary outcomes

  1. Validity of the web-based FFQ

    Assesses the validity of the adapted eNutri FFQ by comparing its results with those from three 24-hour dietary recalls. Validity is evaluated based on nutrient intake measurements.

    Time frame: 14-day period

  2. Reproducibility of the web-based FFQ

    Measures reproducibility by administering the FFQ twice to participants and analyzing the consistency of the results. Consistency of results; statistical measures will be used for analysis.

    Time frame: 14-day period

Secondary outcomes

  1. Usability of the web-based FFQ

    Evaluates usability through participant feedback on a scale (e.g., Likert scale) on the clarity and ease of use of the FFQ and portion size images.

    Time frame: Immediately after the first FFQ administration

  2. Usability Comparison of 24-Hour Recall and web-based FFQ

    Compares dietary intake data obtained from the 24-hour recall method (reference method) with that obtained from the FFQ administered after the second FFQ to assess usability.

    Time frame: Immediately after the second FFQ administration

07

Study locations

1 site
  • Istanbul Medipol University
    İstanbul, Beykoz 34810, Turkey
08

References and documents

Individual participant data

Plan to share: No — The Individual Participant Data (IPD) sharing plan does not include making anonymized data available to other researchers. Instead, data access will be provided only through secure platforms to researchers with approved proposals, ensuring adherence to confidentiality and ethical standards. The data will be shared through publication, with clear terms outlined to safeguard participant privacy.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06536270
Lead sponsor
Medipol University
Collaborators
University of Reading
Responsible party
Merve GÜNEY COŞKUN (Lecturer, Medipol University) — Principal investigator
First posted
Aug 2, 2024
Start date
May 19, 2024
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Last update
Jan 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion